SNY up +1.32% percent right now. $SNY High is at 46.89 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 3:44 PM

SNY up +1.32% percent right now. $SNY High is at 46.89 and the Low 46.55 with current volume of 823,142.

Recent News posted below.

SNY Sanofi-Aventis Sa Recent Headline News

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.00 (-0.12), AGN: 195.85 (+0.61), ACT: 242.96 (-2.77), VRX: 128.11 (+0.12), MDT: 68.86 (+0.15), SLXP: 99.27 (+5.40), SNY: 47.10 (+0.91)

PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.77 (-0.14), SNY: 47.10 (+0.91), PDLI: 8.11 (+0.18)

Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST

MRK: 59.36 (+0.55), AZN: 74.13 (+0.92), AMGN: 161.66 (-1.43), TEVA: 58.23 (+0.19), THRX: 12.94 (-0.50), GSK: 45.90 (+0.74), SNY: 47.10 (+0.91), REGN: 397.97 (+12.00), NVS: 92.61 (-0.02)

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.42 (+0.12), SNY: 47.10 (+0.91), REGN: 397.86 (+11.89)

Look for Shares of Sanofi-Aventis to Potentially Pullback after Yesterday's 1.09% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 47.10 (+0.91)

Sanofi-Aventis Set to Possibly Pullback After Yesterday's Rally of 1.09%
Comtex SmarTrend(R) - Mon Nov 10, 4:29PM CST
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $45.96 to a high of $46.42. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.02 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 47.10 (+0.91)

3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.27 (+0.04), SNY: 47.10 (+0.91), GNW: 8.34 (+0.22), REGN: 397.86 (+11.89)

MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST

NVO: 44.29 (+0.99), PFE: 30.22 (+0.02), LLY: 67.97 (-0.38), MNKD: 6.03 (+0.15), SNY: 47.10 (+0.91)

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 322.77 (-5.10), ALNY: 97.92 (-1.26), ISIS: 51.12 (+3.89), OGXI: 2.11 (-0.02), TEVA: 58.23 (+0.19), RGLS: 20.35 (-0.56), GSK: 45.90 (+0.74), SNY: 47.10 (+0.91)

Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST

ALNY: 97.92 (-1.26), MDCO: 24.20 (-0.16), SNY: 47.10 (+0.91)

VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.61 (-0.09), VVUS: 3.27 (+0.04), AMAG: 34.77 (-0.14), SNY: 47.10 (+0.91)

All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 51.12 (+3.89), SNY: 47.10 (+0.91)

Today's Market: Earnings And News Moving These 5 Stocks
Matthew Smith - at Seeking Alpha - Thu Nov 06, 9:01AM CST

TSLA: 250.89 (+8.96), PRGO: 155.38 (-1.18), QCOM: 69.75 (+0.39), AZN: 74.13 (+0.92), SNY: 47.10 (+0.91)

Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST

AMGN: 161.65 (-1.44), SNY: 47.10 (+0.91), REGN: 397.86 (+11.89)

Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 97.92 (-1.26), AMGN: 161.65 (-1.44), SNY: 47.10 (+0.91), REGN: 397.86 (+11.89)

Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 70.60 (-0.03), TEVA: 58.23 (+0.19), ABBV: 63.63 (-0.16), SNY: 47.10 (+0.91), MNTA: 10.85 (-0.08), NVS: 92.61 (-0.02)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 106.95 (-2.00), ENDP: 67.82 (-1.05), AUXL: 32.61 (-0.09), SHPG: 201.94 (+0.96), DNDN: 0.15 (-0.03), SNSS: 1.68 (-0.02), ABBV: 63.63 (-0.16), SNY: 47.10 (+0.91), MNKD: 6.03 (+0.15), XOMA: 4.02 (+0.13)

Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 117.10 (+0.16), GERN: 2.37 (+0.07), AMGN: 161.65 (-1.44), ABBV: 63.63 (-0.16), AEGR: 21.44 (-0.13), SNY: 47.10 (+0.91), REGN: 397.86 (+11.89)

What We Learned From The MannKind 3rd Quarter Conference Call
Psycho Analyst - at Seeking Alpha - Wed Nov 05, 7:27AM CST

MNKD: 6.03 (+0.15), SNY: 47.10 (+0.91)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honeywell Aerospace Faces Class Action: Deadline Looms

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

York Space Systems Class Action: Deadline Approaches

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

TORRAS Stands Tall with iPhone 18 Pro Cases

By Riley Hayes Updated Oct 24, 2026 Category News Views 150

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...